This is a preview of subscription content, log in via an institution to check access.
References
Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913–20.
Joshi AD, Pontecorvo MJ, Adler L, Stabin MG, Skovronsky DM, Carpenter AP, et al. Radiation dosimetry of florbetapir F 18. EJNMMI Res. 2014;4(1):4.
Neptis plug-01 [package insert] Ver.8. Eli Lilly Japan K.K.; 2019. http://www.info.pmda.go.jp/downfiles/md/PDF/530471/530471_22600BZX00279000_A_01_07.pdf
Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50(11):1887–944.
Rohen JK, Yokochi C. Color atlas of anatomy: a photographic study of the human body. 3rd ed. New York: Igaku-Shoin; 1992.
Netter FH. Atlas of human anatomy. Summit: Ciba-Geigy Corporation; 1989.
Foster DM, Barrett PHR. Developing and testing integrated multicompartmental models to describe a single-input multiple-output study using the SAAM II software system. In: Clifford AJ, Müller H-G, editors. Mathematical modeling of experimental nutrition. New York: Plenum; 1998. p. 59–78.
Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85(3):294–310.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023–7.
Acknowledgements
We thank the staff of Institute of Biomedical Research and Innovation (IBRI) as the contract manufacturer of florbetapir (18F) as an investigational medical product. We also thank Masahiro Sasaki, Akihito Ohnishi, Hiroyuki Nishida, Yasuhiko Ikari, Go Akamatsu, and other staff members of IBRI as the clinical trial site for acquiring PET, blood, and subject data. In addition, we thank Chihiro Namiki (former employee of Eli Lilly Japan K.K.) for his contributions to the development of the outline and reviews of the manuscript. Lastly, the authors would like to thank Shannon Gardell, PhD, and Barbara Nambu, PhD (Syneos Health) for their assistance with preparation of the manuscript and Angela Lorio, ELS, and Antonia Baldo (Syneos Health) for their editorial assistance. MN, TN, YT, KU, and TA are full-time employees of, and minor stockholders in, Eli Lilly and Company. MS has served as a principal investigator of this clinical trial in IBRI sponsored by Eli Lilly and Company/Avid Radiopharmaceuticals. MS was an investigator at IBRI at the time of this work, and IBRI has now merged to be part of Kobe City Medical Center General Hospital. ML and MJP are employees of Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company. ADJ and CB were employees of Avid Radiopharmaceuticals at the time of this work and are now employed by ImaginAb Inc. and Spectrum Dynamics, respectively.
Funding
This research was funded by Eli Lilly and Company and/or one of its subsidiaries.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
NIH ClinicalTrials.gov NCT01660815.
Rights and permissions
About this article
Cite this article
Nakano, M., Nakamura, T., Takita, Y. et al. Radiation dosimetry and pharmacokinetics of florbetapir (18F) in Japanese subjects. Ann Nucl Med 33, 639–645 (2019). https://doi.org/10.1007/s12149-019-01366-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12149-019-01366-5